Eltrombopag (ELT), C25H22N4O4, is a thrombopoietin-receptor agonist, frequently used in the treatment of chemotherapy-induced chronic immune (idiopathic) thrombocytopenic purpura (ITP) and aplastic anemia [1,2]. This evidence concerns the gene MPL and autoimmune thrombocytopenic purpura.